The Patent Finder

Inozyme Pharma, Inc.

Also on record
Records under this name other than patents Inozyme Pharma, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Inozyme Pharma, Inc.

PatentTitleStatus Expires Confidence
US 8,846,603NPP1 Fusion Proteins
In force
 · High confidence
In forceHigh confidence
US 9,540,621NPP1 Fusion Proteins
In force
 · Medium confidence
In forceMedium confidence
US RE49,529Methods of Treating Tissue Calcification
In force
 · Low confidence
In forceLow confidence
US 11,364,284Methods of Treating Myointimal Proliferation
In force
 · High confidence
In forceHigh confidence
US 12,134,790Methods of Improving Cardiovascular Function and Treating Cardiovascular Disease Using a Recombinant Ectonucleotide Pyrophosphatase Phosphodiesterase (NPP1)
In force
 · High confidence
In forceHigh confidence
US 12,698,487Soluble ENPP1 Proteins and Uses Thereof
In force
 · Medium confidence
In forceMedium confidence
US 10,493,135Methods of Treating Tissue Calcification
Surrendered on reissue
Surrendered on reissue May 16, 2023 · Medium confidence
Surrendered on reissueSurrendered on reissue May 16, 2023Medium confidence
15/417,590NPP1 Fusion Proteins
Abandoned
Abandoned Dec 29, 2020
AbandonedAbandoned Dec 29, 2020
17/105,245NPP1 Fusion Proteins
Abandoned
Abandoned Nov 17, 2022
AbandonedAbandoned Nov 17, 2022
17/178,127Treatment of Diseases Involving Deficiency of ENPP1 or ENPP3
Abandoned
Abandoned Sep 26, 2022
AbandonedAbandoned Sep 26, 2022
10 of 23 records shown.
Pro members see all 23.
Pro members: see all 23 records
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited